← Back to Search

Checkpoint Inhibitor

AraG PET Imaging for Lung Cancer

Phase 2

Recruiting

Led By Deepak Behera, MD

Research Sponsored by CellSight Technologies, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status of 0, 1 or 2

Patients with a histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy with concurrent as treatment for advanced/metastatic disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up two years

Awards & highlights

Study Summary

This trial is using AraG PET imaging to study the effectiveness of checkpoint inhibitor therapy for patients with NSCLC.

Who is the study for?

This trial is for adults with advanced non-small cell lung cancer (NSCLC) who are about to start immunotherapy. They should be relatively active and mobile (ECOG status 0-2), have a life expectancy of at least 6 months, and their disease must be measurable by certain medical criteria.Check my eligibility

What is being tested?

The study tests how well [18F]F AraG PET imaging can show the body's immune response to checkpoint inhibitor therapy in NSCLC patients. It aims to measure changes in PET signals before and after treatment, linking these changes to the tumor's visible response on scans.See study design

What are the potential side effects?

[18F]F AraG is a diagnostic agent used for imaging; side effects may include reactions at the injection site or allergic reactions. Checkpoint inhibitors can cause fatigue, skin reactions, inflammation of organs, flu-like symptoms, and other immune-related effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself and perform daily activities.

Select...

I have NSCLC and am set to receive immunotherapy alone or with other treatments for advanced cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ two years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~two years

This trial's timeline: 3 weeks for screening, Varies for treatment, and two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

[18F]F-AraG uptake signal

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

CellSight Technologies, Inc.Lead Sponsor

17 Previous Clinical Trials

261 Total Patients Enrolled

Deepak Behera, MDPrincipal InvestigatorCellSight Technologies, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this medication been approved by the Federal Drug Administration?

"As this is a Phase 2 trial, there is some data indicating that the treatment might be safe but no evidence yet of it being effective. Our team rates the safety as a 2."

Answered by AI

Are patients currently being enrolled in this clinical trial?

"The clinical trial, which is currently recruiting patients according to the website clinicaltrials.gov, was first posted on April 15th, 2021 and updated most recently on April 11th, 2022."

Answered by AI

How many study participants are you working with in total?

"Yes, the clinicaltrials.gov website currently has this study listed as recruiting patients. This trial was first posted on 4/15/2021 and was last edited on 4/11/2022. The researchers conducting this trial are looking to enroll 50 patients from 3 different locations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

2021. "Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04726215.

All > Non Small Cell Lung Cancer > Nsclc